ES3041841T3 - Formulations/compositions comprising a btk inhibitor - Google Patents

Formulations/compositions comprising a btk inhibitor

Info

Publication number
ES3041841T3
ES3041841T3 ES17700821T ES17700821T ES3041841T3 ES 3041841 T3 ES3041841 T3 ES 3041841T3 ES 17700821 T ES17700821 T ES 17700821T ES 17700821 T ES17700821 T ES 17700821T ES 3041841 T3 ES3041841 T3 ES 3041841T3
Authority
ES
Spain
Prior art keywords
ibrutinib
pharmaceutical composition
lymphoma
tablet formulation
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17700821T
Other languages
English (en)
Spanish (es)
Inventor
Manish Gupta
Parikshit Kulkarni
Nair Binuraj Krishnan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES3041841T3 publication Critical patent/ES3041841T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES17700821T 2016-01-19 2017-01-18 Formulations/compositions comprising a btk inhibitor Active ES3041841T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621001987 2016-01-19
PCT/EP2017/050964 WO2017125424A1 (en) 2016-01-19 2017-01-18 Formulations/compositions comprising a btk inhibitor

Publications (1)

Publication Number Publication Date
ES3041841T3 true ES3041841T3 (en) 2025-11-14

Family

ID=57851068

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17700821T Active ES3041841T3 (en) 2016-01-19 2017-01-18 Formulations/compositions comprising a btk inhibitor

Country Status (25)

Country Link
US (3) US20190290650A1 (cg-RX-API-DMAC7.html)
EP (2) EP3405178B1 (cg-RX-API-DMAC7.html)
JP (3) JP7336195B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250025518A (cg-RX-API-DMAC7.html)
CN (2) CN114681462A (cg-RX-API-DMAC7.html)
AR (1) AR107392A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017208473B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018014540B1 (cg-RX-API-DMAC7.html)
CA (1) CA3008576A1 (cg-RX-API-DMAC7.html)
DK (1) DK3405178T3 (cg-RX-API-DMAC7.html)
EA (1) EA201891664A1 (cg-RX-API-DMAC7.html)
ES (1) ES3041841T3 (cg-RX-API-DMAC7.html)
FI (1) FI3405178T3 (cg-RX-API-DMAC7.html)
HK (2) HK1259441A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20251152T1 (cg-RX-API-DMAC7.html)
LT (1) LT3405178T (cg-RX-API-DMAC7.html)
MA (1) MA43650B1 (cg-RX-API-DMAC7.html)
MX (2) MX2018008772A (cg-RX-API-DMAC7.html)
PL (1) PL3405178T3 (cg-RX-API-DMAC7.html)
PT (1) PT3405178T (cg-RX-API-DMAC7.html)
RS (1) RS67236B1 (cg-RX-API-DMAC7.html)
SI (1) SI3405178T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500360T1 (cg-RX-API-DMAC7.html)
TW (1) TWI794153B (cg-RX-API-DMAC7.html)
WO (1) WO2017125424A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2875986C (en) 2012-06-04 2020-06-09 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
ES3041841T3 (en) * 2016-01-19 2025-11-14 Janssen Pharmaceutica Nv Formulations/compositions comprising a btk inhibitor
WO2018065504A1 (en) 2016-10-06 2018-04-12 Janssen Pharmaceutica Nv Processes and intermediates for preparing a btk inhibitor
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2019142207A1 (en) 2018-01-20 2019-07-25 Natco Pharma Limited Pharmaceutical compositions comprising ibrutinib
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib
US12201690B2 (en) 2018-06-15 2025-01-21 Janssen Pharmaceutica Nv Formulations/compositions comprising ibrutinib
US10688050B1 (en) * 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
BR112022007468A2 (pt) * 2019-10-21 2022-07-12 Celgene Corp Composições farmacêuticas compreendendo (s)-2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona e métodos para usar as mesmas

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
WO1993009785A1 (en) 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Risedronate delayed-release compositions
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
ES2180548T3 (es) 1992-10-16 2003-02-16 Nippon Shinyaku Co Ltd Metodo de obtencion de matrices de cera.
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
EP2157524A3 (en) 2003-09-03 2010-12-08 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods for identifying, diagnosing, and predicting survival of lymphomas
NZ601278A (en) 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
WO2013059738A2 (en) * 2011-10-19 2013-04-25 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
CA2875986C (en) 2012-06-04 2020-06-09 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
US20150140085A1 (en) * 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
CA2902613A1 (en) * 2013-03-14 2014-10-02 Pharmacyclics Llc Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
WO2015071432A1 (en) 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
CN104523695A (zh) * 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
ES3041841T3 (en) 2016-01-19 2025-11-14 Janssen Pharmaceutica Nv Formulations/compositions comprising a btk inhibitor
MX2018008771A (es) * 2016-01-19 2018-11-09 Janssen Pharmaceutica Nv Formulaciones/composiciones que comprenden un inhibidor de btk.

Also Published As

Publication number Publication date
RS67236B1 (sr) 2025-10-31
US20230364090A1 (en) 2023-11-16
JP2019506450A (ja) 2019-03-07
HK1259433A1 (zh) 2019-11-29
HK1259441A1 (zh) 2019-11-29
CN114681462A (zh) 2022-07-01
JP7565971B2 (ja) 2024-10-11
CN108472258A (zh) 2018-08-31
JP2024138243A (ja) 2024-10-08
AR107392A1 (es) 2018-04-25
MA43650A (fr) 2018-11-28
MX2022006817A (es) 2022-07-11
HRP20251152T1 (hr) 2025-12-05
EP3405178A1 (en) 2018-11-28
PT3405178T (pt) 2025-10-06
JP7336195B2 (ja) 2023-08-31
BR112018014540A2 (pt) 2018-12-11
CA3008576A1 (en) 2017-07-27
DK3405178T3 (da) 2025-09-22
EP3405178B1 (en) 2025-07-02
US20210169888A1 (en) 2021-06-10
SI3405178T1 (sl) 2025-11-28
AU2017208473A1 (en) 2018-07-12
KR20180102150A (ko) 2018-09-14
SMT202500360T1 (it) 2025-11-10
TW201737918A (zh) 2017-11-01
WO2017125424A1 (en) 2017-07-27
JP2022105006A (ja) 2022-07-12
MA43650B1 (fr) 2025-09-30
TWI794153B (zh) 2023-03-01
BR112018014540B1 (pt) 2024-02-27
FI3405178T3 (fi) 2025-09-30
US20190290650A1 (en) 2019-09-26
EP4663247A2 (en) 2025-12-17
CN108472258B (zh) 2024-05-24
PL3405178T3 (pl) 2025-11-12
LT3405178T (lt) 2025-11-10
MX2018008772A (es) 2018-11-09
AU2017208473B2 (en) 2022-04-21
EA201891664A1 (ru) 2019-02-28
KR20250025518A (ko) 2025-02-21

Similar Documents

Publication Publication Date Title
ES2971597T3 (es) Formulaciones farmacéuticas del inhibidor de la tirosina quinasa de Bruton
US20220339157A1 (en) Formulations/Compositions Comprising a BTK Inhibitor
JP7565971B2 (ja) Ｂｔｋ阻害剤を含む製剤／組成物
HK40076908A (en) Formulations/compositions comprising a btk inhibitor
HK40107203A (en) Pharmaceutical formulations of a bruton's tyrosine kinase inhibtor